I am also looking forward to news from Dr. Jay reg
Post# of 148110
CytoDyn Announces Preliminary Results from 30 mTNBC Patients Treated with Leronlimab. Decreases in CAMLs after 4 Doses of Leronlimab were Identified in Over 70% of Patients and were Associated with a 450% Significant Increase in Overall Survival at 12-Month Analysis.
This is from
Mon, Jul 19, 2021, 3:00 AM
Cheers